Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

HC Wainwright & Co. Reiterates Buy on First Wave BioPharma

HC Wainwright & Co. analyst Yi Chen reiterates First Wave BioPharma (NASDAQ:FWBI) with a Buy.

byBenzinga Newsdesk

January 26, 2023

1 minute read

HC Wainwright & Co. analyst Yi Chen reiterates First Wave BioPharma (NASDAQ:FWBI) with a Buy.

Morgan Stanley Maintains Equal-Weight on NextEra Energy Partners, Lowers Price Target to $93

By Benzinga Newsdesk

Today, 2:18 AM

Morgan Stanley analyst Stephen Byrd maintains NextEra Energy Partners (NYSE:NEP) with a Equal-Weight and lowers the price target from $95 to $93.

NEP

Mizuho Initiates Coverage On Insmed with Buy Rating, Announces Price Target of $28

By Benzinga Newsdesk

Today, 2:18 AM

Mizuho analyst Graig Suvannavejh initiates coverage on Insmed (NASDAQ:INSM) with a Buy rating and announces Price Target of $28.

INSM

iPower Fiscal 2022 Revenue Grows 47%, Here Are The Details

By Vuk Zdinjak

Today, 2:18 AM

iPower Inc. (NASDAQ: IPW), released its financial results for its fiscal fourth quarter and full year ended June 30, 2022, revealing fiscal 2022 revenue of $79.4 million, a 47% increase year-over-year.

IPW

DA Davidson Maintains Buy on Beauty Health, Lowers Price Target to $24

By Benzinga Newsdesk

Today, 2:18 AM

DA Davidson analyst Linda Bolton Weiser maintains Beauty Health (NASDAQ:SKIN) with a Buy and lowers the price target from $35 to $24.

SKIN

HC Wainwright & Co. Reiterates Buy on First Wave BioPharma

Related Posts

Morgan Stanley Maintains Equal-Weight on NextEra Energy Partners, Lowers Price Target to $93

Mizuho Initiates Coverage On Insmed with Buy Rating, Announces Price Target of $28

iPower Fiscal 2022 Revenue Grows 47%, Here Are The Details

DA Davidson Maintains Buy on Beauty Health, Lowers Price Target to $24